Tier 4 — mechanistic
Co-therapy with S-adenosylmethionine and nicotinamide riboside improves t-cell survival and function in Arts Syndrome (PRPS1 deficiency)
Molecular genetics and metabolism reports
2021
26; 100709
Bibliography
- PubMed
- PMID 33532242
- PubMed Central
- PMC7823043
- Funding
- The authors reported no dedicated study funding; supporting institute research received Victorian Government infrastructure support.
- Competing interests
- A complete competing-interest declaration is not specified in the accessible publication information.
Study snapshot
| Design | Clinical case report |
|---|---|
| Model | Human participants |
| Sample | One 3-year-old boy with Arts syndrome |
| Intervention | SAM with NR co-therapy |
| Duration | Individual clinical and laboratory follow-up |
| Endpoints | T-cell function; purine metabolites; clinical status |
What the study showed, in plain terms
Key findings
What this study can and cannot tell us
Editorial review
Reviewed by the Biohack Blueprint research team
Last verified
